期刊
EXPERIMENTAL AND THERAPEUTIC MEDICINE
卷 13, 期 3, 页码 845-850出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2017.4038
关键词
scleral necrosis; pterygium; Tenon's membrane; systemic immunosuppressive therapy
资金
- National Natural Science Foundation of China [81170876, 31271029, 81320108010]
- Science and Technology Commission of Shanghai [13ZR1423600, 12ZR1417300]
The present study aimed to investigate the efficacy of tailored treatment for the management of scleral necrosis following pterygium surgery. A series of nine cases of scleral necrosis following pterygium excision between September 2009 and September 2012 were included. In cases where ischemia was the cause of scleral necrosis, Tenon's membrane covering (TMC) surgery was performed. For cases with surgically-induced necrotizing scleritis (SINS), systemic immunosuppressive therapy following surgical repair of the scleral defect was administered in the form of oral prednisolone (starting dose, 30-60 mg/day). Five patients with ischemic scleral necrosis received TMC postoperatively. Four patients with SINS received various doses of oral prednisolone according to their systematic immune state. All patients had successful postoperative results except one with rheumatoid arthritis, who postoperatively developed scleral patch graft melting within 2 weeks. Following aggressive immunosuppressive treatment, the scleral patch graft was saved. In conclusion, patients achieved positive results using tailored treatment according to the pathogenesis of their scleral necrosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据